Status:
COMPLETED
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
Lead Sponsor:
Emory University
Collaborating Sponsors:
Janssen, L.P. - Investigator Initiated Studies Program
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospita...
Eligibility Criteria
Inclusion
- Primary diagnosis of schizophrenia or schizoaffective disorder
- 4 or more admissions to psychiatric hospital in past year, OR minimum of 2 hospital admissions and at least 2 incarcerations in the previous year
- Medicaid recipient
- Patients requiring concomitant non-antipsychotic psychotropic medication (mood stabilizing, antidepressants, anxiolytics)
Exclusion
- Past or current psychiatric disorder, other than schizophrenia or schizoaffective disorder
- Drug or alcohol dependence
- Serious, unstable medical illness or any acute medical condition
- Pregnant or lactating females
- Prior Risperdal Consta treatment
- Non-English speaking
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00313391
Start Date
December 1 2005
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grady Hospital
Atlanta, Georgia, United States